Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: Results of two randomized, double-blind, placebo-controlled, single-dose studies

Clinical Therapeutics

Volumn 28, Issue 7, 2006, Pages 1022-1034

  Daniels, Stephen E ^a   Desjardins, Paul J ^a   Bird, Steven R ^b   Smugar, Steven S ^b   Tershakovec, Andrew M ^b  

^a Premier Research   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

analgesia; oral surgery; rofecoxib; valdecoxib

Indexed keywords

PLACEBO; ROFECOXIB; VALDECOXIB;

ADOLESCENT; ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENTAL SURGERY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; POSTOPERATIVE PAIN; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TOOTH DISEASE; TOOTH EXTRACTION; TOOTH PAIN;

ADIPONECTIN; AGED; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; ENDPOINT DETERMINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; JAPAN; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; PRAVASTATIN; TRIGLYCERIDES;

EID: 33748603458     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.07.005     Document Type: Article

References (32)

1. Litkowski L., Christensen S., Adamson D., et al. Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: A randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model. Clin Ther. 27 (2005) 418-429
2. Ahmad N., Grad H., Haas D., et al. The efficacy of nonopioid analgesics for postoperative dental pain: A metanalysis. Anesth Prog. 44 (1997) 119-126
3. Dionne R., and Berthod C. Therapeutic uses of nonsteroidal anti-inflammatory drugs in dentistry. Crit Rev Oral Biol Med. 12 (2001) 315-330
4. Verburg K., Maziasz T., Weiner E., et al. Cox-2-specific inhibitors: Definition of a new therapeutic concept. Am J Ther. 8 (2001) 49-64
5. 2 pp following 1528. Bombardier C., Laine L., Reicin A., et al., VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
6. [published correction appears in Gut. 2003;52:1800]. Hawkey C., Laine L., Simon T., et al., Rofecoxib Rheumatoid Arthritis Endoscopy Study Group. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: A multicentre, randomised, double blind study. Gut. 52 (2003) 820-826
7. Watson D., Yu Q., Bolognese J., et al. The upper gastroin-testinal safety of rofecoxib vs. NSAIDs: An updated combined analysis. Curr Med Res Opin 20 (2004) 1539-1548
8. Van Hecken A., Schwartz J., Depre M., et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40 (2000) 1109-1120
9. Hegi T., Bombeli T., Seifert B., et al. Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac. Br J Anaesth 92 (2004) 523-531
10. Desjardins P., Mehlisch D., Chang D., et al. The time to onset and overall analgesic efficacy of rofecoxib 50 mg: A meta-analysis of 13 randomized clinical trials. Clin J Pain 21 (2005) 241-250
11. Morrison B., Fricke J., Brown J., et al. The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials. J Am Dent Assoc 131 (2000) 1729-1737
12. Morrison B., Christensen S., Yuan W., et al. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial. Clin Ther. 21 (1999) 943-953
13. Chang D., Fricke J., Bird S., et al. Rofecoxib versus codeine/acetaminophen in postoperative dental pain: A double-blind, randomized, placebo- and active comparator-controlled clinical trial. Clin Ther. 23 (2001) 1446-1455
14. Chang D., Desjardins P., Chen E., et al. Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: A randomized, placebo-controlled clinical trial. Clin Ther. 24 (2002) 490-503
15. Korn S., Vassil T., Kotey P., and Fricke Jr. J. Comparison of rofecoxib and oxycodone plus acetaminophen in the treatment of acute pain: A randomized, double-blind, placebo-controlled study in patients with moderate to severe postoperative pain in the third molar extraction model. Clin Ther. 26 (2004) 769-778
16. Malmstrom K., Fricke J., Kotey P., et al. A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: A single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model. Clin Ther. 24 (2002) 1549-1560
17. Malmstrom K., Daniels S., Kotey P., et al. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther. 21 (1999) 1653-1663
18. Desjardins P., Shu V., Recker D., et al. A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology 97 (2002) 565-573
19. Daniels S., Desjardins P., Talwalker S., et al. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J Am Dent Assoc. 133 (2002) 611-621
20. Fricke J., Varkalis J., Zwillich S., et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther. 9 (2002) 89-97
21. Christensen K., and Cawkwell G. Valdecoxib versus rofecoxib in acute postsurgical pain: Results of a randomized controlled trial. J Pain Symptom Manage 27 (2004) 460-470
22. Bresalier R., Sandler R., Quan H., et al., Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 352 (2005) 1092-1102
23. FDA Talk Paper. Bextra Label Updated with Boxed Warning Concerning Severe Skin Reactions and Warning Regarding Cardiovascular Risk (December 9 2004). http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01331.html
24. US Food and Drug Administration. Alert for Healthcare Professionals: Valdecoxib (marketed as Bextra) (April 7, 2005). http://www.fda.gov/cder/drug/InfoSheets/HCP/valdecoxibHCP.htm Accessed December 9, 2005
25. Vioxx (rofecoxib tablets and oral suspension) [prescribing information] (2002), Merck & Co, Inc., Whitehouse Station, NJ
26. Bextra (valdecoxib tablets) [prescribing information] (2001), Pharmacia Corporation, Skokie, Ill
27. Cohen M., and Simecek J. Effects of gender-related factors on the incidence of localized alveolar osteitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79 (1995) 416-422
28. Caso A., Hung L., and Beirne O. Prevention of alveolar osteitis with chlorhexidine: A meta-analytic review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99 (2005) 155-159
29. Torres-Lagares D., Serrera-Figallo M., Romero-Ruiz M., et al. Update on dry socket: A review of the literature. Med Oral Patol Oral Cir Bucal 10 (2005) 81-85
30. Blum I. Contemporary views on dry socket (alveolar osteitis): A clinical appraisal of standardization, aetiopathogenesis and management: A critical review. Int J Oral Maxillofac Surg 31 (2002) 309-317
31. Renton T., Smeeton N., and McGurk M. Factors predictive of difficulty of mandibular third molar surgery. Br Dent J. 190 (2001) 607-610
32. FDA Decision Memo. Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. Accessed November 1, 2005 (April 6, 2005). http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf Accessed November 1, 2005